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Abstract
Background: To synthesize and evaluate the impact of implementing post-2010 World Health Organization (WHO) prevention of
mother-to-child transmission (PMTCT) guidelines on attainment of PMTCT targets.
Methods: Retrospective and prospective cohort study designs that utilized routinely collected data with a focus on provision and
utilization of the cascade of PMTCT services were included. The outcomes included the proportion of pregnant women who were
tested during their antenatal clinic (ANC) visits; mother-to-child transmission (MTCT) rate; adherence; retention rate; and loss to
follow-up (LTFU).
Results:Of the 1210 references screened, 45 met the inclusion criteria. The studies originated from 14 countries in sub-Saharan
Africa. The highest number of studies originated fromMalawi (10) followed by Nigeria and South Africa with 7 studies each. More than
half of the studies were on option A while the majority of option B+ studies were conducted in Malawi. These studies indicated a high
uptake of human immunodeﬁciency virus (HIV) testing ranging from 75% in Nigeria to over 96% in Zimbabwe and South Africa. High
proportions of CD4 count testing were reported in studies only from South Africa despite that in most of the countries CD4 testing
was a prerequisite to access treatment. MTCT rate ranged from 1.1% to 15.1% and it was higher in studies where data were
collected in the early days of the WHO 2010 PMTCT guidelines. During the postpartum period, adherence and retention rate
decreased, and LTFU increased for both HIV-positive mothers and exposed infants.
Conclusion: Irrespective of which option was followed, uptake of antenatal HIV testing was high but there was a large drop off
along later points in the PMTCT cascade. More research is needed on how to improve later components of the PMTCT cascade,
especially of option B+ which is now the norm throughout sub-Saharan Africa.
Abbreviations: AIDS = acquired immunodeﬁciency syndrome, ANC = antenatal clinic, ART = antiretroviral therapy, DRC =
Democratic Republic of Congo, EID= early infant diagnosis, HIV= human immunodeﬁciency virus, LTFU= lost to follow-up, MTCT=
mother-to-child transmission, NVP = nevirapine, PMTCT = prevention of mother-to-child transmission, WHO = World Health
Organization.
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1. Introduction
The Joint United Nations Program on human immunodeﬁcien-
cy virus (HIV)/acquired immunodeﬁciency syndrome (AIDS)
over the past 2 decades has documented the heavy burden and
impact of HIV onmothers and infants living in resource-limited
settings. Among the 260,000 new pediatric infections of
HIV worldwide in 2012, 90% of new cases occurred in sub-
Saharan Africa.[1] The use of antiretroviral therapy (ART) by
HIV-positive mothers is the cornerstone of strategies to
prevention of mother-to-child transmission (PMTCT) during
the ante-partum and peri-partum periods and for the duration
of breastfeeding.[2]
The World Health Organization (WHO) in 2010 revised
guidelines and offered 2 options: option A and option B. Under
option A, pregnant women with a CD4≥350cells/mL receive
ART prophylaxis from 14 weeks gestation through 1 week
postpartum, single-dose nevirapine (NVP) at delivery, and daily
lamivudine from delivery through 1 week postpartum. Their
infants receive daily NVP from birth through 1 week after
the cessation of breastfeeding.Womenwith CD4350cells/mL
or WHO clinical stage 3 or 4 disease are put permanently on
triple-drug ART. Under option B, all women receive triple-drug
ART from 14 weeks gestation through the cessation of
breastfeeding, and infants receive a daily NVP or zidovudine
dose from birth to 4 to 6 weeks.[2] In 2013, WHO revised its
guidelines for the treatment and prevention of HIV and
recommended that all pregnant and breastfeedingHIV-infected
women, regardless of CD4 cell count, should continue ART
for life known as “option B+” while their infants receive
daily NVP or zidovudine from birth to 4 to 6 weeks.[3] Option
B+ is now a norm in sub-Saharan Africa, with all the 21 global
plan countries implementing it except for Nigeria as of
October 2015.[4]
Effective PMTCT programmes require women and their
infants to receive a cascade of interventions including uptake
of antenatal services and HIV testing during pregnancy, use of
ART by pregnant women living with HIV, safe child birth
practices and appropriate infant feeding uptake, with infant
prophylaxis, HIV testing, and other postnatal health care services
following delivery.[5] The global community committed to
accelerate progress for PMTCT through an initiative whose
goals were to eliminate new pediatric HIV infection by 2015 and
improve maternal, newborn and child health, and survival in the
context of HIV.[6] Elimination of new pediatric infections has not
been met, so there is a need to investigate why some programs are
not effective. This systematic review of the literature was
performed to evaluate the impact of implementing the WHO
post-2010 PMTCT guidelines in order to inform practices which
could help reach PMTCT targets.
2. Methods
2.1. Data sources
The following databases were searched for articles published
from January 2010 to October 2016: Africa Wide Information,
Medline, Embase, and reference lists from publications provided
additional articles. The search was limited to English language
journals for studies in sub-Saharan Africa. The following search
terms and their variations were combined: prevention of mother
to child transmission of HIV; PMTCT cascade; PMTCT options;
effectiveness of PMTCT; PMTCT option A; PMTCT option B;
PMTCT option B+; antiretroviral treatment; ART; antenatal
care; HIV; HIV-exposed infants’ health outcomes; infant feeding;
early infant diagnosis (EID), adherence; retention in care; and loss
to follow-up (LTFU).
2.2. Study selection
The searched results were exported using reference manage-
ment software Endnote 7.3 and duplicates were removed. The
titles, abstracts, and full texts of potentially relevant studies
were reviewed for eligibility. An adapted Preferred Reporting
Items for Systematic and Meta-Analysis (PRISMA) ﬂow chart
was drawn (ﬂow diagram). The selected studies had to include
data collected post the WHO 2010 PMTCT guidelines. The
inclusion criteria were: retrospective and prospective cohort
study designs that utilized routinely collected data with a
focus on provision and utilization of the cascade of PMTCT
services; studies with particular interest in WHO option A, B,
or B+ implementation; and studies from countries which
had adopted WHO post-2010 PMTCT guidelines during the
data collection period, and studies which evaluated implemen-
tation of post 2010 PMTCT guidelines. Qualitative studies,
randomized controlled trials, reviews, commentaries, editori-
als, and modeling studies were excluded. Two independent
reviewers (SGM and TM) reviewed the full text articles for
inclusion, exclusion and extracted data on outlined outcomes.
Ethical approval was granted from London School of Tropical
Medicine and Hygiene Research Ethics Committee (Ref:
12086).
2.3. Data extraction
Data were extracted using a standardized data extraction form
which summarized key information from relevant studies. The
following information was extracted: proportion of pregnant
women who were tested during their antenatal clinic (ANC)
visits; proportion of women who tested HIV-positive; proportion
of women who were already on ART before pregnancy;
proportion of women who received their HIV test results;
proportion of women tested for CD4 cell count; type of PMTCT
option for mothers and their infants; adherence of women to
ART; infant feeding methods; infant age when polymerase
chain reaction (PCR) was done; mother-to-child transmission
(MTCT) rate; proportion of infants reported to die or be LTFU as
missing 3 consecutive clinic visits; and retention rate which is
the continuous engagement from diagnosis in a package of
prevention, treatment, support, and care services. In case of
studies where data collection began before 2010 only post-2010
data were extracted.
3. Summary of results
3.1. Study characteristics
A total of 944 potentially eligible full text articles out of 2913
studies based on titles and abstracts were identiﬁed. Forty-ﬁve
met the inclusion criteria (ﬂow diagram) and they originated from
14 countries in sub-Saharan Africa (Table 1). The highest number
of studies originated from Malawi (10) followed by Nigeria and
South Africa with 7 studies each. The period of data collection
was from 2010 to April 2015. The sample sizes for the selected
studies ranged from 113 to 2,215,090 participants; the largest
sample sizes were from the studies that utilized national data
from South Africa and Ghana.
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3.2. Uptake of ANC services
The data onHIV testing during ANC visits were extracted from 8
studies (Table 1) conducted in Malawi,[7–9] Nigeria,[10,11]
Ghana,[12] Zimbabwe,[13] and South Africa.[14] These studies
indicated a high uptake of HIV testing ranging from 75% in
Nigeria to over 96% in Zimbabwe and South Africa. The high
uptake of HIV testing could have been an attributable to policy
changes in integrating HIV testing in ANC and shifting from opt-
in to opt-out testing.
The proportion of women who were already on ART prior to
ANC visits was reported in 6 studies, from Malawi,[7–9]
Zimbabwe,[13] Kenya,[15] and Zambia.[16] In Zimbabwe only
7% of the women were already on ART during their ANC visits
while in Malawi, implementation of option B+, resulted in an
increase of women who were already on ART before
pregnancy[7–9] from 30% before option B+ to 48% after option
B+ adaptation. In a matched cohort study of option A and B, in 4
sites receiving external technical support for the provision of
PMTCT-related care in Zambia, 48% of women were already on
ART prior to their ﬁrst ANC visit.[16] Findings are not
representative of PMTCT service delivery in Zambia as a whole,
since the sites receive technical support for the provision of
PMTCT-related care from the Boston University PMTCT
Integration Project through the President’s Emergency Plan for
AIDS Relief (PEPFAR). External support can also inﬂuence
health facility characteristics and operational aspects of a facility
such as capacity, location, stafﬁng, and services provided.
Four out of the 7 studies that had information on CD4 count
testing were from South Africa[17–20] and the rest from Kenya,[15]
Zambia,[16] andMozambique.[21] The proportion of womenwho
had CD4 testing during ANC visits from Kenya, Zambia, and
Mozambique was below 60% despite the fact that over the data
collection period of these studies, CD4 testing was supposed to be
a prerequisite to access care. In South Africa the proportion of
women tested for CD4 count increased from 66% in 2010 to
76% in 2012 according to a study that utilized national data.[19]
3.3. Exposure to PMTCT options
Thirty-ﬁve (78%) studies reported on option A (Tables 1 and 2)
and they were from the 14 representative countries with South
Africa contributing 7 studies.[14,17–19,22–24] Implementation of
option B+ was investigated in Nigeria,[25,26] Malawi,[7–9,27–32]
Mozambique,[33] Zimbabwe,[34] and Ethiopia[35,36] in 16 studies
which were synthesized. The 2 studies which reported in all 3
options (A, B, and B+) were conducted in Malawi[29] and
Nigeria[25] where the data collection covered a longer period.
3.4. Infant outcomes
The MTCT rate was reported in 29 studies (Table 1) and ranged
from 1.1% to 15.1%. MTCT rate was high (above 10%) mainly
in studies where data were collected in the early days[37–42] of the
WHO 2010 PMTCT guidelines although South Africa reported a
low MTCT rate of 2% during the same period.[20] In Zambia,
there was a reduction inMTCT rate from 12% in 2010[37] to 3%
in a retrospective study conducted from 2011 to 2014.[43] The
lowest MTCT rate of 1.1% was reported from Nigeria[26];
however, the author indicated that the study involved HIV-
positive women who booked for antenatal care in a tertiary
institution and were likely to be wealthier and more educated
than the general population and perhaps more likely to adhere to
ART and other PMTCT interventions
3.5. Exposure to PMTCT options and MTCT rate
In a study fromCameroon, under option A, theMTCT rate was
3.7% for infant mother pairs who both received prophylaxis;
16.2% when only the mothers received prophylaxis; 12% for
mothers without prophylaxis whose infants received NVP; and
31.3% when neither mother or infant received prophylaxis.[44]
In Zambia, lower rates of MTCT were associated with both
mother and infant receiving prophylaxis: 4.2% compared to
20.1% in a no intervention group at 0 to 6 weeks.[37] In South
Africa, in-utero transmission rate was highest among women
who required ART but did not initiate treatment (8.5%)
compared to 2.7% and 0.4% amongwomenwho received ART
and women who were not eligible for ART and received
prophylaxis under option A.[14]
In Ethiopia, absence of maternal ART was signiﬁcantly and
independently associated with maternal to child transmission of
HIV (adjusted odds ratio [aOR]=5.02, 95% CI: 2.43, 10.4).[45]
Results from 2 studies that compared option A and B+ from
Ethiopia[36] and Malawi,[8] both conﬁrmed supremacy of option
B+ over A in terms ofMTCT rate. In Ethiopia, none of the infants
whose mothers received option B+ had a positive PCR result
while the MTCT rate for those under option A was 3.9%.[36] In
Malawi, the MTCT rate was 2.9% under Option A, 1.9% under
option B+, and 1.1% for infants whose mothers received ART for
their own health.[8]
Figure 1 shows MTCT rates at the end of data collection year
and according to which option was used; only studies showing
overall MTCT rates, not rates at younger ages when HIV
transmission may have been ongoing in a breastfeeding
population, are shown. Option A had higher MTCT rates in
most of the studies under review; however, most option A studies
preceded the option B+ studies. The general functions of the
PMTCT programs have been improving over time with studies
carried out after 2013 showing lower MTCT rates even under
option A.
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Figure 1. Key – The numbers in brackets are study references and the points
are the MTCT rate. MTCT=mother-to-child transmission.
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3.6. Timing of ART initiation and MTCT
In Kenya where an MTCT rate of 8.9% was reported, lack of
maternal use of ART at the time of delivery was associated with
increased risk of MTCT for infants of women who were on
option A and B.[15] In Nigeria, MTCT (0.4%) was lower among
women on ART before pregnancy compared to women who
started ART during pregnancy or delivery which was at 2%.[46]
3.7. Impact of infant feeding on MTCT
The impact of infant feeding mode was not explored in most in the
analysis of most studies under this review with only 13 studies
providing results (Table 2). Exclusive breastfeeding is commonly
measured through household surveys by asking mothers/caregivers
of sample infants less than 6 months of age regarding intake in the
previous day and night. However, there is a lack of uniformity of
methods used for collecting exclusive breastfeeding data in the
countries under review. Infant feeding methods were reported in
studies from Zambia,[37] Malawi,[7] Democratic Republic of Congo
(DRC),[40] Ethiopia,[36,45] Cameroon,[42,47] Nigeria,[26,46,48,49]
South Africa,[18] and Tanzania.[39] High levels of exclusive
breastfeeding were reported, with Malawi reporting that 99% of
HIV-exposed infantsbeingexclusivelybreastfed in theﬁrst 6months.
MTCT of HIV was signiﬁcantly higher with mixed feeding
(aOR: 6.7, 95% CI 1.6–28.3; P= .009) in Cameroon under
option A exposure.[42] Similarly inNigeria,MTCTwas higher for
mixed fed infants at 14.2% compared to 3.73% for exclusively
breastfed infant and 2.43% for exclusively formula-fed infants at
18months.[49] This was consistent with a study in Ethiopia where
mixed infant feeding practices were signiﬁcantly and indepen-
dently associated with MTCT of HIV (aOR=4.18, 95% CI:
1.59, 10.99).[45]
Lower rates of MTCT were found in children who never
breastfed in Zambia at 2.5% at 0 to 6 weeks compared to 6.5%
those who had been breastfed under option A exposure.[37]
3.8. Early Infant diagnosis
EID of HIV by PCR was reported in 20 studies from 8 countries
(Table 1). The uptake of EID ranged from less than 60% in
Nigeria[25] and Zambia[37] to 100% in 2012 according to South
African national data where it increased from 87% in 2010.[19]
The age at which PCR was done ranged from 4 weeks to 18
months. In South Africa, 80%of exposed infants had PCR results
at 6 weeks,[24] whereas in Malawi 52% underwent testing at 6 to
12 weeks and 28% tested at 12 months.[31]
3.9. Impact of age at ﬁrst PCR on MTCT
Age at ﬁrst PCR had an impact on the MTCT of HIV-exposed
infants. In Tanzania, the proportion of HIV-infected infants was
higher among infants who appeared later for HIV testing (18% at
3–6 months) than among those who presented earlier (6.4% at
1–2 months) under option A implementation.[39] The Tanzanian
observations were in agreement with the Ethiopian study which
reported that late enrolment to the exposed infant follow-up
clinic was signiﬁcantly and independently associated withMTCT
of HIV (aOR=2.89, 95% CI: 1.35, 6.21).[45]
3.10. ART initiation of HIV-positive infants
ART initiation of HIV-positive infants is a key stage of the
PMTCT cascade. In this review, it was reported in 3 studies from
DRC,[40] Zambia,[41] and Nigeria.[11] Among HIV-infected
infants in DRC, 97% enrolled in 2011 to 2012 were initiated
on ART; this was an increase from 61% for infants enrolled in
2007 to 2008.[40] Lower rates were reported in Zambia where
67% of infants who tested positive started ART by the end of the
study[41] and Nigeria where 75% of HIV-positive infants were
initiated on ART.[11]
3.11. Retention in care
Retention in routine maternal-infant HIV care of HIV exposed
infants was explored 3 studies from Zambia, Malawi, and
Rwanda. In Zambia, the retention rate of HIV-exposed infants
under option A, at 6 months after delivery was 62% compared to
30% of HIV-unexposed infants under the same ongoing routine
care conditions.[16] In Malawi, 72% of HIV-exposed infants
remained in care after 12 months under option B+,[31] whereas in
Rwanda under option B, infants’ 12-month retention was 81%
(95% CI: 76%, 86%).[53]
In Malawi, the retention in HIV care of women initiated on
option B+was 85%, compared to 93% after 2 years among those
initiated on ART because of clinical or CD4 cell count criteria.[29]
These results were consistent with the ﬁndings from Rwanda
where mothers eligible for ART for their own health were better
retained across all the time periods, 66% (CI: 59%, 73%),
compared with those not eligible and receiving ART solely for
PMTCT, 47% (CI: 37%, 57%), at 12 months, P< .001.[53]
Another Malawian study highlighted that initiation of ART on
the same day asHIV diagnosis was independently associatedwith
reduced retention in the ﬁrst 6 months (aOR 2.27; 95% CI:
1.34–3.85; P= .002) in under option B+.[9]
In a retrospective record review of women presenting to
antenatal care or maternal and child health services at 34 health
facilities in rural Zimbabwe, retention in ART care after 6
months of option B+ initiation was 83%.[34] In contrast,
retention for Rwandan mothers exposed to option B was 68%
at 6 weeks postdelivery, decreasing to 58% by 12 months.[53]
3.12. Lost to follow-up (LTFU)
Data on the magnitude of LTFU (missing 3 consecutive clinic
visits) along the PMTCT cascade were reported in 9 studies
(Table 2) from Malawi,[27,28,51] Tanzania,[38] Kenya,[15]
Nigeria,[10,25] and Ethiopia.[35,36] In the studies from Malawi
and Ethiopia, this was explored in the context of option B+ while
in the other countries it was explored under option A.
In Tanzania,[38] 61% of infants receiving treatment were LTFU
at the time of review, despite the high proportion of guardians
and parents who returned for PCR results (92% in 2010 and
98% in 2011). The results were consistent with a study from
Malawi were 48% of the HIV-exposed infants were declared
LTFU in the database although 96% of the them in the cohort
had their PCR test done at 24 months.[54] However, Nigeria
reported low rates of LTFU for HIV-infected infants of less than
15%[11,46] despite that the studies evaluated different PMTCT
options. In Kenya, LTFU increased with the age of infants with
9.6% of enrolled infants not returning for any follow-up care,
26.4% dropping out by 9 months and 39% by 18 months of
age.[15]
In Ethiopia under option B+ implementation, the cumulative
proportions of women LTFU at 6, 12, and 24 months were 12%,
15%, and 23%, respectively.[35] Similar results were reported in
Malawi where cumulative incidence of LTFU by year 2 was
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24.5% (95%CI, 23.2%–25.8%) among women who started
ART during pregnancy, 20.2% (95%CI, 18.3%–22.2%) among
those who started ARTwhile breastfeeding, and 17.0% (95%CI,
15.2%–18.8%) among those who were neither pregnant nor
breastfeeding when they started treatment.[30]
The independent risk factors for LTFU were younger maternal
age at ART initiation, missing CD4 cell count at ART initiation,
ART initiation on the same day of diagnosis, and starting ART at
hospital.[35] The risk of being LTFU was higher in “B+ pregnant”
(adjusted sub-hazard ratio [asHR]: 2.77; 95% CI: 2.18–3.50;
P< .001) and “B+ lactating” (asHR: 1.94; 95% CI: 1.37–2.74;
P< .001) compared to women on ART for their own health in
Mozambique.[33]
3.13. Adherence
Adherence to ART drugs for PMTCT by the mothers was
reported in 2 studies (Table 2) from Malawi[51] and Zambia.[43]
Adherence during the postpartum period in Zambia[43] ranged
from 71% to 84% at different times postpartum. The results of
the study were consistent with the Malawian study were 70% of
women exposed to option B+, who started ART during
pregnancy and breastfeeding adhered adequately during the ﬁrst
2 years of ART.[30] However, default and incomplete adherence
were more common in the option B+ compared to the option A in
Malawi,[51] where 4% of women in the option B+ cohort had less
than 95% adherence compared to 2% for the option A cohort.
4. Discussion
The global plan toward the elimination of new HIV infections
among children by 2015 and keeping their mothers alive
prioritized 21 countries in sub-Saharan Africa. The studies in
the review originated from 14 of the priority countries. The
studies show a continued decline in the incidence of HIV among
children, as indicated by low MTCT rates, but the target of a
90% reduction by 2015 was not met, reduction in incidence
being only 76% in the 21 priority countries.[55] South Africa
reported low MTCT rates under option A implementation[24]
even from the results of the facility-based cross-sectional study
conducted in 2010.[56] This could have been as a result of their
health system which is better resourced than in most of the
countries under review.
Many of the studies on the impact of infant feeding methods
and exposure to various ART regimens were conducted before
the 2010 WHO PMTCT.[55,57] Although infant feeding results
were available from only a minority of studies in this review, the
results of the review are in agreement with the ﬁndings which
led to the current guidelines. In the countries under review
breastfeeding is very common, and breastfed infants have an
increased risk of MTCT of HIV.[58] Mixed feeding is also a
common practice in sub-Saharan Africa and is an additional risk
for postnatal HIV transmission.[59] As revealed by the studies
from Tanzania[39] and Ethiopia,[45] where there was increase in
MTCT over time, continued breastfeeding in the face of low
adherence to ART treatment, is a risk.
Option B+ which initiates lifelong ART to all pregnant and
breastfeeding women is now widespread in sub-Saharan Africa,
with all the 22 global plan countries implementing it except for
Nigeria. As of October 2015, option B+ was being nationally
implemented in 14 (Angola, Burundi, Cameroun, Chad,
Ethiopia, Kenya, Lesotho, Malawi, South Africa, Swaziland,
Tanzania, Uganda, Zambia, and Zimbabwe) out of the 21
countries in sub-Saharan Africa, and scale-up continues in 6
countries (Botswana, Cote d’Ivoire, DRC, Ghana, Mozambique,
andNamibia).[4] In this review, Implementation of option B+ was
investigated in Nigeria,[25,26] Malawi,[7–9,27–32] Mozambique,[33]
Zimbabwe,[34] and Ethiopia.[35,36] Most studies came from
Malawi since they were the pioneers of this option; hence, there is
a need to explore the impact of implementing the option B+
guidelines and identifying missed opportunities along the
PMTCT cascade in other countries which have adopted it.
The implementation of option B+ in Malawi resulted in a 5-
fold increase in the numbers of pregnant women being enrolled
on ART. Nonetheless, default and incomplete adherence were
more common in option B+ implementation.[43,51] These results
were consistent with a qualitative study conducted in Tanzania
among mothers who were put on option B+ during pregnancy
who indicated various reasons for poor adherence to ART, which
included lack of motivation to continue ART after weaning the
child and protecting the child from becoming infected, stigma,
and poverty.[60] There is also a need to adjust operational
practices related to quality of counseling as it has been indicated
to be a predictor of adherence to treatment.[61] Moreover, a
recent study suggested that retention in all postnatal programs,
including those outside the context of HIV, is poor globally,
elaborating the need for evidence-based intervention strategies
and further research on the drivers of disengagement.[62]
The retention in care of HIV-infected and lactating mothers
under option B+ was poor and driven by early losses.[9,27–29,34,53]
Hence, implementation of option B+ requires that policy makers
rethink ways of ensuring optimal adherence to ART for maximal
suppression of viral replication and avoidance of drug resistance.
One possibility is to explore the use of cell phone SMS which has
been found to be useful in Africa for improving the quality of care
and follow-up of people with HIV/AIDS.[63,64]
The consolidated guidelines recommend that HIV-exposed
infants be tested for HIV between 6 and 8 weeks, at the end of
breastfeeding, and at any point they present with illness.[3]
However, in the studies under review the retention rate tended
to decrease during the postpartum period.[16,27–29,32] This
reduction in postpartum retention rate implies that HIV-exposed
infants will be detached from the health system, thus missing
opportunities for PCR testing. A systematic review of mostly sub-
Saharan countries found that about a 3rd of HIV-exposed
children in standard PMTCT programs fall out of care in 3
months after delivery and a further 45% stop care after their ﬁrst
HIV test.[65] Furthermore, low rates of infected infants are
initiated on ART despite being PCR-tested,[32,38] raising concerns
on the beneﬁts of EID and the referral to care and treatment of
these infected infants. Similar results were reported by Chatterjee
et al,[66] in their descriptive analysis of national EID programs in
4 countries where only 22% to 38% of infected infants were
initiated on ART. There is a need for strategic and technical
developments for ensuring that drop-out rates along the PMTCT
cascade are minimal.
4.1. Limitations of the study
Themajor limitation of the review is that the results of most of the
study ﬁndings may not be representative of the general health
care systems in the countries reviewed as only 2 studies from
Ghana and South Africa used national data for analysis. There
are also profound variations in the implementation of PMTCT
programs across countries. For instance, in Nigeria MTCT was
reported to be 1.1%,[26] which was largely attributed to the study
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population which comprised wealthier and more educated
women than the general population. There is a research gap of
evaluating PMTCT interventions using large cohorts that can be
generalized to the whole population.
The limitations of the data sources of this review are mainly
due to the retrospective nature posing problems of incomplete
recordings. Moreover, the data used in these studies were
originally collected for different purposes from this review and
therefore hard to compare data when a lot of time points differ
because of different timings of key outcomes. However, the
advantage of using routinely collected data is that research will be
conducted in a timely and cost-efﬁcient manner as data are
already collected and available for analysis.[67]
All the studies reported challenges in the documentation of
routine services, linkage of HIV diagnosis to care, and active
follow-up of those enrolled in care. The data collection systems
often lack immediacy as many are paper-based with records
completed at each facility and collated centrally. This is likely to
be in challenge in most sub-Saharan countries; and therefore,
there is a need to improve management of health information
systems through the use of modern technology.
5. Conclusion
Irrespective of which option was followed, uptake of antenatal
HIV testing was high but there was a large drop off along later
points in the PMTCT cascade. More research is needed on how to
improve later components of the PMTCT cascade, especially of
option B+which is now the norm throughout sub-Saharan Africa.
There is research gap for studies that investigated the full
cascade of interventions that include uptake of antenatal services
and HIV testing during pregnancy, use of ART by pregnant
women living with HIV, appropriate infant feeding, uptake of
infant HIV testing, and other postnatal health care services in the
context of the PMTCToption B+ interventions. In view of the gap
there is a need for implementation research evaluating real world
effectiveness of the 2010 WHO PMTCT guidelines speciﬁcally
option B+.
Acknowledgments
The authors thank the SEARCH (Sustainable Evaluation through
Analysis of Routinely Collected HIV data) Project funded by the
Bill & Melinda Gates Foundation grant number OPP1084472
for the support.
References
[1] UNAIDS. Global plan towards the elimination of New HIV infections
among children by 2015 and keeping their mothers alive. 2011. http://
www.unaids.org/sites/default/ﬁles/media_asset/20110609_JC2137_Glo
bal-Plan-Elimination-HIV-Children_en_1.pdf. Accessed August 17,
2015.
[2] UNAIDS. Global HIV/AIDS response epidemic update and health sector
progress towards universal access. 2011. http://www.unaids.org/sites/
default/ﬁles/media_asset/20111130_UA_Report_en_1.pdf. Accessed
August 17, 2015.
[3] UNAIDS. Countdown to Zero: Global Plan Towards the Elimination of
newHIV Infections among Children by 2015 and Keeping their Mothers
Alive 2011–2015. Geneva: 2011. ﬁle:///C:/Users/lsh1405741/Down-
loads/elimination-of-new-hiv-among-children-in-africa-by-2015-
08112013.pdf. Accessed August 17, 2015.
[4] The Interagency Task Team on the Prevention and Treatment of HIV
Infection in Pregnant Women MaC. Option B+ countries and PMTCT
regimen 2015. Available from: http://emtct-iatt.org/b-countries-and-
pmtct-regimen/. [Accessed Aug 17, 2016]
[5] Padian NS, et al. HIV prevention transformed: the new prevention
research agenda. Lancet 2011;378:269–78.
[6] UNAIDS, Countdown to Zero: Global Plan Towards the Elimination of
new HIV Infections among Children by 2015 and Keeping their Mothers
Alive 2011–2015. 2011: Geneva. http://www.unaids.org/sites/default/
ﬁles/media_asset/20121211_Women_Out_Loud_en_1.pdf. Accessed
December 22, 2015.
[7] Price AJ, et al. Uptake of prevention of mother-to-child-transmission
using option B+ in northern rural Malawi: a retrospective cohort study.
Sex Transm Infect 2014;90:309–14.
[8] KimMH, Ahmed S, Hosseinipour MC, et al. The impact of option b+ on
the antenatal PMTCT Cascade in Lilongwe, Malawi. J Acquir Immune
Deﬁc Syndr 2015;68:77.
[9] Chan AK, et al. Same day HIV diagnosis and antiretroviral therapy
initiation affects retention in Option B+ prevention of mother-to-child
transmission services at antenatal care in Zomba District, Malawi. J Int
AIDS Soc 2016;19:20672.
[10] Okusanya BO, Ashimi AO, Aigere EO, et al. Scaling up prevention of
PMTCT of HIV infection to primary health centres in Nigeria: ﬁndings
from two primary health centres in North West Nigeria. Afr J Reprod
Health 2013;17:130–7.
[11] Pharr JR, et al. Linkage to care, early infant diagnosis, and perinatal
transmission among infants born to HIV-infected Nigerian mothers:
evidence from the healthy beginning initiative. J Acquir Immune Deﬁc
Syndr 2016;72(Suppl 2):S154–60.
[12] Dako-Gyeke P, Dornoo B, Ayisi Addo S, et al. Towards elimination of
mother-to-child transmission of HIV in Ghana: an analysis of national
programme data. BMC Int J Equity Health 2016;15:
[13] Gonese E, et al. Is Zimbabwe ready to transition from anonymous
unlinked sero-surveillance to using prevention of mother to child
transmission of HIV (PMTCT) program data for HIV surveillance?:
results of PMTCT utility study. BMC Infect Dis 2016;16:97.
[14] Hussain A, Moodley D, Naidoo S, et al. Esterhuizen pregnant women’s
access to PMTCT and ART services in South Africa and implications for
universal antiretroviral treatment. PLoS Med 2011;6:e27907.
[15] Nduati EW, et al. Outcomes of prevention of mother to child
transmission of the human immunodeﬁciency virus-1 in rural Kenya-a
cohort study. BMC Public Health 2015;15:1008.
[16] Scott CA, et al. Uptake, outcomes, and costs of antenatal, well-baby, and
prevention of mother-to-child transmission ofHIV services under routine
care conditions in Zambia. PLoS One 2013;8:e72444.
[17] Schnippel K,Mongwenyana C, Long LC, et al. Delays, interruptions, and
losses from prevention of mother-to child transmission of HIV services
during antenatal care in Johannesburg, South Africa: a cohort analysis.
BMC Infect Dis 2015;6:46.
[18] Technau KG, et al. Timing of maternal HIV testing and uptake of
prevention of mother-to-child transmission interventions among women
and their infected infants in Johannesburg, South Africa. J Acquir
Immune Deﬁc Syndr 2014;65:e170–8.
[19] Bhardwaj S, Barron P, Pillay Y, et al. Elimination of mother-to-child
transmission of HIV in South Africa: rapid scale-up using quality
improvement. S Afr Med J 2014;104:239–43.
[20] Hussain A, et al. Pregnant women’s access to PMTCT and ART services
in South Africa and implications for universal antiretroviral treatment.
PLoS One 2011;6:e27907.
[21] Gimbel S, et al. What does high and low have to do with it? Performance
classiﬁcation to identify health system factors associated with effective
prevention of mother-to-child transmission of HIV delivery in
Mozambique. J Int AIDS Soc 2014;17:18828.
[22] Moodley P, Parboosing R, Moodley D. Reduction in perinatal HIV
infections in KwaZulu-Natal, South Africa, in the era of more effective
prevention of mother to child transmission interventions (2004–2012).
J Acquir Immune Deﬁc Syndr 2013;63:410–5.
[23] Sherman GG, et al. Laboratory information system data demonstrate
successful implementation of the prevention of mother-to-child trans-
mission programme in South Africa. S Afr Med J 2014;104(3 Suppl
1):235–8.
[24] Ibeto M, Giddy J, Cox V. Closing the gaps: steps towards elimination of
mother-to-child transmission of HIV. S Afr J HIV Med 2014;15:107–9.
[25] Rawizza HE, et al. Loss to follow-up within the prevention of mother-to-
child transmission care cascade in a large ART program in Nigeria. Curr
HIV Res 2015;13:201–9.
[26] Okafor I, Eqwu U, Obi S, et al. Virtual elimination of mother-to-child
transmission of human immunodeﬁciency virus in mothers on highly
active antiretroviral therapy in Enugu, South-Eastern Nigeria. Ann Med
Health Sci Res 2014;4:615–8.
Gumede-Moyo et al. Medicine (2017) 96:40 www.md-journal.com
11
[27] Tweya H, et al. Understanding factors, outcomes and reasons for loss to
follow-up amongwomen inOption B+ PMTCT programme in Lilongwe,
Malawi. Trop Med Int Health 2014;19:1360–6.
[28] Tenthani L, et al. Retention in care under universal antiretroviral therapy
for HIV-infected pregnant and breastfeeding women (‘Option B+’) in
Malawi. AIDS 2014;28:589–98.
[29] Koole O, et al. Improved retention of patients starting antiretroviral
treatment in Karonga District, northern Malawi, 2005–2012. J Acquir
Immune Deﬁc Syndr 2014;67:e27–33.
[30] Haas AD, Msukwa MT, Egger M, et al. Adherence to antiretroviral
therapy during and after pregnancy: cohort study on women receiving
care in Malawi’s Option B+ Program. Clin Infect Dis 2016;63:1227–35.
[31] Martínez Pérez G, Metcalf C, Garone D, et al. HIV testing and retention
in care of infants born to HIV-infected women enrolled in ‘Option B+’,
Thyolo, Malawi. Public Health Action 2014;4:102–4.
[32] Ng’ambi WF, et al. Follow-up and programmatic outcomes of HIV-
exposed infants registered in a large HIV centre in Lilongwe, Malawi:
2012–2014. Trop Med Int Health 2016;21:995–1002.
[33] Llenas-Garcia J, et al. Retention in care of HIV-infected pregnant and
lactating women starting ART under Option B+ in rural Mozambique.
Trop Med Int Health 2016;21:1003–12.
[34] Dzangare J, et al. HIV testing uptake and retention in care of HIV-
infected pregnant and breastfeeding women initiated on ’Option B+’ in
rural Zimbabwe. Trop Med Int Health 2016;21:202–9.
[35] Mitiku I, et al. Factors associated with loss to follow-up amongwomen in
Option B+ PMTCT programme in northeast Ethiopia: a retrospective
cohort study. J Int AIDS Soc 2016;19:20662.
[36] Olana T, Bacha T, Worku TW, et al. Early infant diagnosis of HIV
infection using DNA-PCR at a referral center: an 8 years retrospective
analysis BMC. AIDS Res Ther 2016;13:29.
[37] Torpey K, et al. Analysis of HIV early infant diagnosis data to estimate
rates of perinatal HIV transmission in Zambia. PLoS One 2012;7:
e42859.
[38] Chiduo MG, Mmbando BP, Theilgaard ZP, et al. Early infant diagnosis
of HIV in three regions in Tanzania; successes and challenges. BMC
Public Health 2013;13:910.
[39] Mwendo EM, et al. Effectiveness of prevention of mother-to-child HIV
transmission programmes in Kilimanjaro region, northern Tanzania.
Trop Med Int Health 2014;19:267–74.
[40] Feinstein L, Edmonds A, Chalachala JL, et al. Temporal changes in the
outcomes of HIV-exposed infants in Kinshasa, Democratic Republic of
Congo during a period of rapidly evolving guidelines for care
(2007–2013). AIDS 2014;28:301–11.
[41] Sutcliffe CG, van Dijk JH, Hamangaba F, et al. Turnaround time for
early infant HIV diagnosis in rural Zambia: a chart review. PLoS One
2014;9:e87028.
[42] Noubiap JJ, Bongoe A, Demanou SA. Mother-to-child transmission of
HIV: ﬁndings from an Early Infant Diagnosis program in Bertoua,
Eastern Cameroon. Pan Afr Med J 2013;15:65.
[43] Okawa S, Chirwa M, Ishikawa N, et al. Longitudinal adherence to ART
drugs for PMTCT of HIV in Zambia. BMC Pregnancy Childbirth
2015;15:258.
[44] Saounde Temgoua EM, et al. HIV-1 early infant diagnosis is an effective
indicator of the prevention of mother-to-child transmission program
performance: experience from Cameroon. Curr HIV Res 2015;13:
286–91.
[45] Koye DN, Zeleke BM. Mother-to-child transmission of HIV and its
predictors among HIV-exposed infants at a PMTCT clinic in northwest
Ethiopia. BMC Public Health 2013;13:398.
[46] Sagay AS, et al. Mother-to-child transmission outcomes of HIV-exposed
infants followed up in Jos North-Central Nigeria. Curr HIV Res 2015;
13:193–200.
[47] Saounde TEM, Nkenfou CN, Zoung-Kanyi Bissek AC, et al. HIV-1 early
infant diagnosis is an effective indicator of the prevention of mother-to-
child transmission program performance: experience from Cameroon.
Curr HIV Res 2016;13:286–91.
[48] Banwat SB, Ochekpe NA, Auta A, et al. Anti retroviral drug prophylaxis
in prevention of mother-to-child transmission of HIV infection in a
treatment centre in Jos, Nigeria. J Pharm Bioresourc 2015;11:93–100.
[49] Anigilaje EA, et al. HIV-free survival according to the early infant-feeding
practices; a retrospective study in an anti-retroviral therapy programme
in Makurdi, Nigeria. BMC Infect Dis 2015;15:132.
[50] Bannink-Mbazzi F, Lowicki-Zucca M, Ojom L, et al. High PMTCT
program uptake and coverage of mother, their partners, and babies in
Northern Uganda: achievements and lesson learnt over 10 years of
implementation (2002–2011). J Acquir Immune Deﬁc Syndr 2013;62:
138–45.
[51] Kamuyango AA, et al. One-year outcomes of women started on
antiretroviral therapy during pregnancy before and after the implemen-
tation of Option B+ in Malawi: a retrospective chart review. World J
AIDS 2014;4:332–7.
[52] Mugerwa JN, Namukwaya Z, Kekitiinwa A, et al. Early Infection
Among UgandanHIV-Exposed InfantsWhoseMothers ReceivedOption
B+ vs Option A, In: International Antiviral Society, Boston, Massachu-
setts, USA, March 3–6, 2014.
[53] Woelk GB, Ndatimana D, Behan S, et al. Retention of mothers and
infants in the prevention of mother-Tochild transmission of HIV
programme is associated with individual and facility-level factors in
Rwanda. J Int AIDS Soc 2016;19:20837.
[54] Ng’ambi WF, Ade S, Harries AD, et al. Follow-up and programmatic
outcomes of HIV-exposed infants registered in a large HIV centre in
Lilongwe, Malawi: 2012–2014. Trop Med Int Health 2016;21:
995–1002.
[55] World Health Organization. New data on the prevention of mother-to-
child transmission of HIV and their policy implications: conclusions and
recommendations. Technical Consultation on behalf of the UNFPA/
UNICEF/WHO/UNAIDS Inter-Agency Task Team on Mother-to-Child
Transmission of HIV. Geneva: WHO, 2001. http://apps.who.int/iris/
bitstream/10665/66851/1/WHO_RHR_01.28.pdf. Accessed September
20, 2015.
[56] Goga AE, et al. First population-level effectiveness evaluation of a
national programme to prevent HIV transmission from mother to child,
South Africa. J Epidemiol Commun Health 2015;69:240–8.
[57] Little KM, et al. A review of evidence for transmission of HIV from
children to breastfeeding women and implications for prevention. Pediatr
Infect Dis J 2012;31:938–42.
[58] Coutsoudis A, et al. Late postnatal transmission of HIV-1 in breast-fed
children: an individual patient data meta-analysis. J Infect Dis
2004;189:2154–66.
[59] Iliff PJ, et al. Early exclusive breastfeeding reduces the risk of postnatal
HIV-1 transmission and increases HIV-free survival. AIDS 2005;19:
699–708.
[60] Ngarina M, et al. Reasons for poor adherence to antiretroviral therapy
postnatally in HIV-1 infected women treated for their own health:
experiences from the Mitra Plus study in Tanzania. BMC Public Health
2013;13:450.
[61] Ebuy H, Henock Y, Mussie A. Level of adherence and predictors of
adherence to the Option B+ PMTCT programme in Tigray. Northern
Ethiop Int J Infect Dis 2015;33:123–9.
[62] Myer L, Phillips TK. Beyond Option B+”: understanding antiretroviral
therapy (ART) adherence, retention in care and engagement in ART
services among pregnant and postpartum women initiating therapy in
Sub-Saharan Africa. J Acquir Immune Deﬁc Syndr 2017;75(Suppl 2):
S115–22.
[63] Siedner MJ, Santorino D, Lankowski AJ, et al. A combination SMS and
transportation reimbursement intervention to improve HIV care
following abnormal CD4 test results in rural Uganda: a prospective
observational cohort study. BMC Med Global Health 2015;13:160DOI
10.1186/s12916-015-0397-1.
[64] Chang LW,Njie-Carr V, Kalenge S, et al. Perceptions and acceptability of
mHealth interventions for improving patient care at a community-based
HIV/AIDS clinic in Uganda: a mixed methods study. AIDS Care
2014;25:874–80.
[65] Sibanda EL, et al. The magnitude of loss to follow-up of HIV-exposed
infants along the prevention of mother-to-child HIV transmission
continuum of care: a systematic review and meta-analysis. AIDS
2013;27:2787–97.
[66] Chatterjee A, et al. Implementing services for Early Infant Diagnosis
(EID) of HIV: a comparative descriptive analysis of national programs in
four countries. BMC Public Health 2011;11:553.
[67] Grzeskowiak LE, Gilbert AL, Morrison JL. Methodological challenges
in using routinely collected health data to investigate long-term
effects of medication use during pregnancy. Ther Adv Drug Saf
2012;4:27–37.
Gumede-Moyo et al. Medicine (2017) 96:40 Medicine
12
